LMLei Ma

Lei Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Lei Ma has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • H. Eric Xu

    CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    1 shared publication
  • Leying Zhu

    Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China

    1 shared publication
  • Miao Liang

    Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China

    1 shared publication
  • Silin Zhang

    Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China

    1 shared publication
  • Wei Yi

    Guangzhou Medical University

    1 shared publication
  • Xianglin Zhou

    Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China

    1 shared publication

Latest Publications

  • Open Access

    Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition

    by Xiawen Liu, Xiufen Zheng, Lei Ma, Ziqing Yao, Xuehua Zheng, Miao Liang, Xinhong Wu, Silin Zhang, Xianglin Zhou, Leying Zhu, et al.

    Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.